Latest news

Take Part Of The Next Anti-CTLA4 Explicyte Shuttle

05 / 19 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-CTLA4 immunotherapy and/or evaluation of its ability to potentiate CTLA4 blockade mostly relies on immunocompetent mouse models in which the response to CTLA4 blockade has been already validated (see our recent case study).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-CTLA4 treated group and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-CTLA4 mAb).

The next explicyte shuttle is scheduled for the 21th of June!

Anti-CTLA-4 Response In Mouse Tumor Syngeneic Models

04 / 27 / 2016

In order to improve the benefit of anti-CTLA4 immunotherapy the current challenges the pharma industry are facing are the:

  • Development and evaluation of novel test compounds able to synergize with anti-CTLA-4
  • Discovery of novel molecular mechanisms underlying the resistance to anti-CTLA4 blockade
  • Identification of biomarkers capable to predict response to anti-CTLA4 therapy

At a preclinical stage, these points can be addressed using immunocompetent animal models in which the response to reference immune checkpoint inhibitors is validated. This is why we characterized the clinical response to anti-CTLA4 immunotherapy in mouse syngeneic tumor models and selected the most sensitive to further investigate the cellular and molecular features of the immune response associated with clinical efficacy.

Preclinical Mouse Tumor Models Of Immune Checkpoint Inhibition

01 / 28 / 2016

To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies. Starting with basic measurements of in vivo efficacy, our in vivo services extends to comprehensive biomarker studies, to determine the in vivo mechanism of action of novel treatments.


Syngeneic Mouse Model Of Glioblastoma

01 / 22 / 2016

Syngeneic Mouse Model Of Glioblastoma

To assess the in vivo efficacy and mechanism of action of novel therapeutic strategies for brain cancer, Explicyte has validated a syngeneic mouse tumor model of glioma, which closely mimics human glioblastoma (GBM) in terms of tumor progression and immune response. A key advantage of this model, based on the GL261-Luc2 murine glioma cell line, relies on the possibility of quantifying tumor growth in live animals by bioluminescence imaging along the study.

IDO1 Expression Does Not Strictly Match L-Kynurenine Production In Cancer Tissue

04 / 21 / 2015

This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues. The study suggests that the in situ detection of L-Kynurenine could serve to stratify patients in the context of cancer immunotherapies targeting tryptophan catabolic enzymes: indoleamine 2,3-dioxygenase (IDO-1/-2) or tryptophan 2,3-dioxygenase 2 (TDO2).